ArticleMikrochimica acta2026
Development of a portable label-free electrochemical sensor modified with AuNPs/g-C
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development and application of a lab-made screen-printed electrode (SPE) modified with electrodeposited gold nanoparticles (AuNPs), graphitic carbon nitride (g-C3N4) and cetyltrimethylammonium bromide (CTAB) for the electrochemical determination of uric acid (UA) is reported. The SPE/AuNPs/g-C3N4@CTAB platform was optimized to enhance its electroactive surface area, conductivity, and charge-transfer kinetics, as confirmed through scanning electronic microscopy, energy-dispersive x-ray spectroscopy, Raman spectroscopy, contact angle analysis, cyclic voltammetry, and electrochemical impedance spectroscopy. Differential pulse voltammetry measurements demonstrated a linear response for UA concentrations between 50 and 600 µmol L⁻¹, with a limit of detection of 1.95 µmol L⁻¹, fully covering clinically relevant ranges. The sensor exhibited high selectivity against common interferents, as well as excellent stability and optimal performance at physiological pH of 7.0, consistent with UA dissociation equilibria. The application of the SPE/AuNPs/g-C3N4@CTAB sensor for UA detection in human whole blood, serum, and plasma samples showed promising results comparable to those obtained from standard enzymatic colorimetric assays, confirming the analytical reliability of the device. The computational analysis by DFT calculations demonstrated that the Eads of UA to the complete modified sensor decreased at − 0.23 eV when compared to the SPE/AuNPs/g-C3N4. This reduction provides strong theoretical evidence supporting the influence of the CTAB modifier on the UA detection mechanism. Overall, the proposed modified SPE platform provides a simple, cost-effective, and portable alternative tool for UA monitoring in clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.